These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 27734073

  • 1. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding.
    Quintard H, Viard D, Drici MD, Ruetsch C, Samama CM, Ichai C.
    Thromb Haemost; 2017 Jan 05; 117(1):196-197. PubMed ID: 27734073
    [No Abstract] [Full Text] [Related]

  • 2. [Dabigatran specific antidote: new safety level in oral anticoagulation].
    MMW Fortschr Med; 2015 Nov 05; 157(19):78-9. PubMed ID: 26953416
    [No Abstract] [Full Text] [Related]

  • 3. Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury.
    Novak JE, Alamiri K, Yee J.
    Am J Kidney Dis; 2018 Jan 05; 71(1):137-141. PubMed ID: 28549534
    [Abstract] [Full Text] [Related]

  • 4. [Safer in everyday clinical care].
    Petersen PF, Grottke O.
    MMW Fortschr Med; 2015 Nov 05; 157(19):79. PubMed ID: 26953417
    [No Abstract] [Full Text] [Related]

  • 5. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK, Santiago RA, Dew RB, Berliner N, Connors JM, Connell NT, Tucker JK.
    Pharmacotherapy; 2016 Oct 05; 36(10):e160-e165. PubMed ID: 27581709
    [Abstract] [Full Text] [Related]

  • 6. Idarucizumab (Praxbind)--an antidote for dabigatran.
    Med Lett Drugs Ther; 2015 Nov 23; 57(1482):157-8. PubMed ID: 26583604
    [No Abstract] [Full Text] [Related]

  • 7. Reversal of dabigatran-associated bleeding using idarucizumab: review of the current evidence.
    Giustozzi M, Verso M, Agnelli G, Becattini C.
    J Thromb Thrombolysis; 2017 Nov 23; 44(4):527-535. PubMed ID: 28913672
    [Abstract] [Full Text] [Related]

  • 8. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
    van der Wall SJ, van Rein N, van den Bemt B, Kruip MJHA, Meijer K, Te Boome LCJ, Simmers TA, Alings AMW, Tieleman R, Klok FA, Huisman MV, Westerweel PE.
    Europace; 2019 Mar 01; 21(3):414-420. PubMed ID: 30339226
    [Abstract] [Full Text] [Related]

  • 9. How Should Canadian Pharmacy Departments Utilize Idarucizumab?
    Tangedal K, Semchuk W, Bolt J.
    Can J Hosp Pharm; 2016 Mar 01; 69(5):429-430. PubMed ID: 27826164
    [No Abstract] [Full Text] [Related]

  • 10. Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran.
    Sié P.
    Drug Des Devel Ther; 2016 Mar 01; 10():1683-9. PubMed ID: 27274201
    [Abstract] [Full Text] [Related]

  • 11. Idarucizumab for Reversal of Dabigatran: Single-Center Real-World Experience.
    Sheikh-Taha M.
    Am J Cardiovasc Drugs; 2019 Feb 01; 19(1):59-64. PubMed ID: 30203330
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Goal-directed administration of antidote for reversal of dabigatran anticoagulation].
    Lindeman E.
    Lakartidningen; 2017 Dec 05; 114():. PubMed ID: 29292966
    [Abstract] [Full Text] [Related]

  • 15. Reversal of dabigatran requiring hemodialysis, fresh frozen plasma, and 2 doses of idarucizumab in a patient with acute kidney injury.
    Sheikh-Taha M.
    Am J Health Syst Pharm; 2019 Jan 01; 76(1):9-12. PubMed ID: 31381100
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.